Laboratorios Farmaceuticos Rovi, S.A.
LABFF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $210 | $160 | $155 | $199 |
| % Growth | 31.8% | 3.1% | -22.2% | – |
| Cost of Goods Sold | $63 | $54 | $64 | $91 |
| Gross Profit | $148 | $105 | $90 | $108 |
| % Margin | 70.2% | 65.9% | 58.4% | 54.4% |
| R&D Expenses | $0 | $11 | $6 | $9 |
| G&A Expenses | $0 | $0 | $0 | $38 |
| SG&A Expenses | $0 | $35 | $35 | $60 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $22 |
| Other Operating Expenses | $71 | $31 | $26 | $7 |
| Operating Expenses | $71 | $77 | $67 | $75 |
| Operating Income | $76 | $28 | $23 | $33 |
| % Margin | 36.3% | 17.5% | 14.9% | 16.5% |
| Other Income/Exp. Net | -$1 | -$1 | -$0 | -$1 |
| Pre-Tax Income | $76 | $27 | $23 | $32 |
| Tax Expense | $18 | $5 | $5 | $9 |
| Net Income | $58 | $22 | $18 | $23 |
| % Margin | 27.6% | 13.5% | 11.7% | 11.7% |
| EPS | 1.13 | 0.42 | 0.35 | 1.81 |
| % Growth | 169% | 20% | -80.7% | – |
| EPS Diluted | 1.13 | 0.42 | 0.35 | 1.81 |
| Weighted Avg Shares Out | 51 | 51 | 51 | 51 |
| Weighted Avg Shares Out Dil | 51 | 51 | 51 | 51 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $0 |
| Interest Expense | $1 | $1 | $1 | $2 |
| Depreciation & Amortization | $7 | $4 | $7 | $0 |
| EBITDA | $84 | $31 | $30 | $33 |
| % Margin | 39.9% | 19.5% | 19.5% | 16.4% |